Trastuzumab: In HER2-positive metastatic gastric cancer

Drugs

Volumn 70, Issue 17, 2010, Pages 2259-2267

  Croxtall, Jamie D ^a   McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Gastric cancer; Trastuzumab, general

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; TRASTUZUMAB;

ANEMIA; AREA UNDER THE CURVE; CANCER CELL; CANCER INHIBITION; CANCER SCREENING; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; METASTASIS; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PHARMACODYNAMICS; PROGRESSION FREE SURVIVAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 78549272751     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11205900-000000000-00000     Document Type: Review

References (38)

1. Parkin D, Bray F, Ferlay J, et al. Global cancer statistics,. CA Cancer J Clin 2005; 55 (2): 74-108.
2. Shah MA, Kelsen DP. Gastric cancer: a primer on the epi-demiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw 2010 Apr; 8 (4): 437-47.
3. Field K, Michael M, Leong T. Locally advanced and meta-static gastric cancer: current management and new treatment developments. Drugs 2008; 68 (3): 299-317.
4. Roth AD, Ajani J. Docetaxel-based chemotherapy in thetreatment of gastric cancer. Ann Oncol 2003; 14 Suppl. 2: ii41-4.
5. Wagner AD, Wedding U. Advances in the pharmacologicaltreatment of gastro-oesophageal cancer. Drugs Aging 2009; 26 (8): 627-46.
6. Allum WH, Griffin SM, Watson A, et al. Guidelines for themanagement of oesophageal and gastric cancer. Gut 2002 Jun; 50 Suppl. 5: v1-23.
7. Ajani J, Bekaii-Saab T, D'Amico TA, et al. Gastric cancerclinical practice guidelines. J Natl Compr Canc Netw 2006 Apr; 4 (4): 350-66.
8. Moehler M, Lyros O, Gockel I, et al. Multidisciplinarymanagement of gastric and gastroesophageal cancers. World J Gastroenterol 2008 Jun 28; 14 (24): 3773-80.
9. Lordick F, Peschel C, Siewert JR. Antibody-based targetedtherapy for gastric cancer. Gastric Cancer 2005; 8 (4): 206-8.
10. Burstein HJ. The distinctive nature of HER2-positive breastcancers. N Engl J Med 2005 Oct 20; 353 (16): 1652-4.
11. Gravalos C, Jimeno A. HER2 in gastric cancer: a newprognostic factor and a novel therapeutic target. Ann Oncol 2008; 19 (9): 1523-9.
12. Gschwind A, Fischer OM, Ullrich A. The discovery of re-ceptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004 May; 4 (5): 361-70.
13. Plosker GL, Keam SJ. Trastuzumab: a review of its use inthe management of HER2-positive metastatic and early-stage breast cancer. Drugs 2006; 66 (4): 449-75.
14. Ruschoff J, Nagelmeier I, Baretton G, et al. HER2 testingin gastric cancer. what is different in comparison to breast cancer? [in German]. Pathologe 2010 May; 31 (3): 208-17.
15. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2scoring system for gastric cancer: results from a validation study. Histopathology 2008 Jun; 52 (7): 797-805.
16. Meza-Junco J, Au H-J, Sawyer MB. Trastuzumab for gas-tric cancer. Expert Opin Biol Ther 2009; 9 (12): 1543-51.
17. McKeage K, Perry CM. Trastuzumab: a review of its use inthe treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62 (1): 209-43.
18. Perry CM, Wiseman LR. Trastuzumab. Biodrugs 1999 Aug;12 (2): 129-35.
19. Garnock-Jones KP, Keating GM, Scott LJ. Trastuzumab: areview of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 2010; 70 (2): 215-39.
20. Genetech, Inc. Herceptin® (trastuzumab): prescribing in-formation [online]. Available from URL: http://www. accessdata.fda.gov/drugsatfda-docs/ label/2010/103792s52 50lbl.pdf [Accessed 2010 Oct 27].
21. European Medicines Agency. Herceptin: summary of pro-duct characteristics [online]. Available from URL: http:// www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000278/WC500074922.pdf [Accessed 2010 Oct 18].
22. Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab(Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001 Jun 15; 61 (12): 4744-9.
23. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Anti-tumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007; 59 (6): 795-805.
24. Kim SY, Kim HP, Kim YJ, et al. Trastuzumab inhibits thegrowth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008; 32 (1): 89-95.
25. Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: Her-ceptin acts as an anti-angiogenic cocktail. Nature 2002 Mar 21; 416 (6878): 279-80.
26. Hudis CA. Trastuzumab: mechanism of action and use inclinical practice. N Engl J Med 2007 Jul 5; 357 (1): 39-51.
27. Valabrega G, Montemurro F, Aglietta M. Trastuzumab:mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007 Jun; 18 (6): 977-84.
28. Ocana A, Cruz JJ, Pandiella A. Trastuzumab and anti-estrogen therapy: focus on mechanisms of action and resistance. Am J Clin Oncol 2006 Feb; 29 (1): 90-5.
29. Bang Y, Chung H, Xu J, et al. Pathological features of ad-vanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract no. 4556]. J Clin Oncol 2009 May 20; 27: 15S.
30. Plus poster presented at the 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29-Jun 2; Orlando (FL).
31. Chung H, Bang Y, Xu J, et al. Human epidermal growthfactor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing [abstract no. 6511 plus poster]. 15th European Cancer Conference and the 34th Congress of the European Society of Medical Oncology; 2009 Sep 20-24; Berlin.
32. European Medicines Agency. Assessment report for Herceptin[online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR- Assessment-Re port-Variation/human/000278/WC500074921.pdf [Accessed 2010 Oct 19].
33. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase IIstudy of efficacy, safety, and pharmacokinetics of trastu-zumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005 Apr 1; 23 (10): 2162-71.
34. Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmaco-kinetics, safety, and efficacy of trastuzumab administeredevery three weeks in combination with paclitaxel. J Clin Oncol 2003 Nov 1; 21 (21): 3965-71.
35. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab incombination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376 (9742): 687-97.
36. ToGA study - a study of Herceptin (trastuzumab) in com-bination with chemotherapy compared with chemotherapy alone in patients with HER2-positive advanced gastric cancer [ClinicalTrials.gov indentifier NCT01041404].
37. Satoh T, Leon J, Lopez RI, et al. Quality of life results froma phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer [abstract no. 7]. American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 2010 Jan 22-24; Orlando (FL).
38. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab.Drug Saf 2008; 31 (6): 459-67